Bluejay Diagnostics, Inc.

NASDAQ: BJDX · Healthcare · Medical - Devices

PublicHQ Acton, MACIK 0001704287Reports USD

#976 of 1,394 Healthcare companies by revenue

EA Score

34D

FH 33DQ 38GM —SS 21

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, filing timeliness · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$6.8M

Employees

Market cap

$517.0k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$249.0k$249.0k2022

Net income-$6.8M-$6.8M2025

Operating income-$7.0M-$7.0M2025

Total assets$7.1M$7.1M2025

Liabilities$1.1M$1.1M2025

Equity$6.0M$6.0M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Bluejay Diagnostics, Inc. booked $249.0k in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -2750.0% net margin.

Peers · Healthcare

Mednow Inc.——Therapeutic Solutions International, Inc.——Global Roundtable Corporation——BiomX Inc.——

Key facts

CEOIndranil Dey

SectorHealthcare

IndustryMedical - Devices

HeadquartersActon, MA

ExchangeNASDAQ: BJDX

Employees7

IPO date2021-11-10

Latest filings

8-K2026-06-09 8-K2026-06-08 8-K2026-06-02 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-30 8-K2026-04-07 8-K2026-03-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.